A University of Cincinnati study found differences in pancreatic tumors that could help explain why that type of cancer affects some patients differently, potentially leading to more personalized treatments.
Researchers examined 22 pancreatic tumors from patients of different racial backgrounds across the U.S., looking for differences in cancer cells and how the immune system responds to them. The study included seven Black patients and 15 non-African American patients.
The findings were published in the journal Cancer Research.
FDA APPROVES ONCE-DAILY PILL FOR DEADLY CANCER AFTER PATIENTS’ SURVIVAL RATES NEARLY DOUBLE
Tumors from Black patients had fewer of the most common type of pancreatic cancer cells and more cells with a mix of different characteristics, the researchers found.
Some of those cell characteristics have been associated with drug resistance, but the study did not establish whether they affected patients treatment outcomes.
Additionally, tumors from Black patients contained more B cells, a type of immune cell, and larger clusters of immune cells. Researchers found signs that some B cells may suppress the bodys response to cancer, although the significance of these differences is unclear.
PATIENTS REMAIN CANCER-FREE NEARLY 3 YEARS AFTER RECEIVING EXPERIMENTAL IMMUNOTHERAPY
Dr. Raymond Wadlow, a medical oncologist at Inova Schar Cancer Institute in Virginia, said that using immunotherapy to help the immune system attack the disease has been particularly challenging in pancreatic cancer.
“That’s been very difficult to do in pancreatic cancer because the pancreatic tumor subverts the immune system so that it is fighting for it instead of for the host or the rest of the body,” Wadlow, who was not involved in the study, told Fox News Digital.
The study found no significant differences between groups in the major genetic changes known to drive the disease.
Pancreatic cancer is approximately 20% more likely to develop in Black Americans than in non-African Americans, according to the researchers.
WHERE YOU LIVE COULD SHAPE YOUR RISK OF CANCER MORTALITY, STUDY SUGGESTS
The findings highlight the importance of including patients from different backgrounds in cancer research, according to lead study author Nina Steele, Ph.D., an assistant professor in UCs College of Medicine.
“This study shows that ignoring diverse ancestry in leaves blind spots in the search for a cure,” she told Fox News Digital.
Wadlow noted that pancreatic cancers can share major DNA mutations but can differ considerably in how their cells behave and interact with nearby immune cells and surrounding tissue.
“Those differences may also vary across patient populations, such as between Black and non-Black patients,” he told Fox News Digital.
“That is potentially important both for understanding disparities in and, ultimately, for developing more individualized treatments.”
Pancreatic cancer can vary f

